Nilai Buku saben Saham: bioaffinitytech.com (BIAF)

The published book value of the share demonstrates the fundamental resilience of bioAffinity Technologies (BIAF), while the 8.37 level indicates the state of the parameter. The company's dominance in early lung cancer diagnostics is driven by the high accuracy of the CyPath Lung test. Monetization through insurance networks and clinics relies on unique patents. However, the ultimate strength of the market moat depends on FDA approval and widespread insurance coverage.

bioAffinity Technologies (BIAF) ensures the stability of its material base through strict adherence to medical protocols in lung cancer diagnostics. This indicator is calculated as the difference between total assets and liabilities divided by the number of shares, reflecting the actual net asset value; analyzing the historical change in book value per share allows an investor to determine the extent of the market discount relative to the business's fundamental basis.